



Corporate Profile

CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology.

Stock Performance

CTMX (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Financial Status Indicator	C
Price	\$21.57
Change (%)	▼ 0.09 (0.42%)
Volume	1,049,751
52 Week Low	\$10.44
Market Cap	\$828,474,063
Rolling EPS	-1.57
PE Ratio	0
Shares Outstanding	38,408,626

Data as of 12/15/17 4:00 p.m. ET



Recent Headlines

11/28/17

CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic

11/07/17

CytomX Announces Third Quarter 2017 Financial Results and Operational Progress

11/01/17

CytomX to Present at the Jefferies 2017 London Healthcare Conference

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form	Description
12/12/17	4	Statement of changes in beneficial ownership of securities
12/05/17	4	Statement of changes in beneficial ownership of securities
12/05/17	4	Statement of changes in beneficial ownership of securities
12/04/17	8-K	Report of unscheduled material events or corporate event

Data provided by Nasdaq. Minimum 15 minutes delayed.